

# Cellmid Ltd

16:02 05 Oct 2016

## Cellmid Ltd gets boost from study results treating brain cancer

Cellmid Ltd (ASX:CDY) has received results from a pre-clinical collaboration with Complutense University in Spain that suggests the company's midkine antibodies can be used to treat a type of brain cancer.

Cellmid has two business segments, consumer health, which sells products and its midkine (MK) portfolio, which it is looking to clinically develop.

Results from this study show that MK antibodies reduce certain brain tumour sizes in animals.

Currently, there is no effective treatment for this aggressive form of brain cancer known as glioblastoma.

Existing treatments only extend survival from three months to just over a year.

The results of the study add to Cellmid's already significant intellectual property MK assets ready for clinical development.

### Background

Cellmid has two business segments, consumer health and its MK portfolio.

Cellmid holds the largest and most comprehensive portfolio of intellectual property relating to the MK and FGF5 globally.

Cellmid's consumer health division currently sells hair growth products in Japan and Australia, which were developed using FGF5 related intellectual property.

Cellmid aims to follow in the footsteps of FGF5 by commercialising its MK portfolio.

Cellmid has recently set up dedicated subsidiaries, Lynamid Limited and Kinera Limited as part of its clinical development plan to commercialise its MK antibody assets.

### Study details

The study showed that MK antibodies are effective in improving medical cannabis treatment response in animals to glioblastoma.

Medicinal cannabis has a number of benefits in cancer treatment including relieving pain and nausea, and improving appetite.

There is sound scientific evidence that distinct chemical components of

**Price:** A\$0.5

**Market Cap:** A\$28.46M

### 1 Year Share Price Graph



### Share Information

**Code:** CDY

**Listing:** ASX

**52 week High Low**  
0.8p 0.35p

**Sector:** Pharma & Biotech

**Website:** www.cellmid.com.au

### Company Synopsis:

Cellmid Ltd (ASX:CDY) is listed on the Australian Securities Exchange.

### Author:

**Proactive Investors Australia**

**+61 (0)2 9280 0700**

**action@proactiveinvestors.com.au**

cannabis called cannabinoids are potent anticancer agents.

However, as for many cancer drugs, tumours can develop resistance to cannabinoids.

The current study observed that MK antibodies, in combination with the cannabinoid THC, inhibited tumour growth in gliomas that are resistant to THC.

Overcoming THC resistance highlights a potential treatment strategy using MK antibodies.

## Analysis

The results of this study add to the already significant intellectual property assets ready for clinical development by Lyramid.

The higher the value and potential of Lyramid's assets the more opportunities Cellmid has to commercialise them.

Furthermore, the study results provide additional collaboration opportunities with companies focused on improving their existing therapeutic approaches using cannabinoids in the treatment of this type brain cancer.

Cellmid is trading up 40% year to date, currently priced at \$0.034.

**Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.**

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +61 (0)2 9280 0700 [action@proactiveinvestors.com.au](mailto:action@proactiveinvestors.com.au)

## No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.